Tandem Health

+17%

est. 2Y upside i

HealthcareSeries A

Tandem provides a clinician copilot that enables clinicians to focus on providing care, instead of on administrative tasks. Our ambient scribe listens during the patient consultation, transcribes it, and automatically generates a draft medical note that can seamlessly be transferred to your medical record system. Tandem's copilot fully follows GDPR and local patient data laws.

Rank

#1667

Sector

Generative AI for Healthcare

Est. Liquidity

~5Y

Data Quality

Data: Low

The stock is highly risky due to missing financial data and early stage, but the strong moat in European healthcare AI justifies cautious optimism.

Last updated: July 19, 2026

Bull (20%)+180%

Tandem achieves widespread European adoption, leveraging regulatory first-mover advantage and deep EHR integrations. Revenue scales rapidly, exit multiple holds, and dilution is offset by strong growth.

Base (55%)+10%

Moderate growth with steady customer acquisition; valuation grows modestly but is diluted by future funding rounds and competitive pressure. Net return near breakeven.

Bear (25%)-100%

Competition from incumbents like Nuance and well-funded startups, or regulatory setbacks, lead to failure. Preferred stack consumes all proceeds, common stock worthless.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

2975%

Total funding of $59.5M represents ~30% of assumed $200M valuation, giving preferred shareholders significant liquidation preference over common stock.

Dilution Risk

moderate

With $50M Series A raised in mid-2025, runway is likely ~18-24 months; a Series B within 2 years is probable, diluting current holders by 15-25%.

Secondary Liquidity

none

No secondary market activity observed; illiquid until a liquidity event.

Questions to Ask at the Interview

Strategic questions based on Tandem Health's data — designed to show you've done your homework.

1
“How does Tandem plan to expand beyond clinical documentation into adjacent workflows?”
2
“What is the customer acquisition cost and gross retention rate for the subscription model?”
3
“Given the regulatory moat, what is the path to profitability and when do you expect to raise the next round?”

Community

Valuation Sentiment

Our model estimates +17% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.